INVA zieht bullische Sicht von Cantor aus der Stärke wiederkehrender Lizenzgebühren

What happened: Cantor Fitzgerald upgraded Insmed Incorporated (INSM) to 'Overweight' on June 10, raising its price target from $230 to $235, citing upcoming data from the company's phase 3 clinical trial for its drug, Arikayce. Meanwhile, Cantor reiterated its 'Overweight' rating on Innoviva, Inc. (INVA) on April 8, maintaining a $32 price target, appreciating the stability of the company's recurring royalty streams. Dauntless Investment Group increased its stake in Innoviva by 116,863 shares in Q1 2021, valuing the position at approximately $2.52 million.

Market impact: The bullish views from Cantor Fitzgerald drove optimism in the healthcare sector, specifically for companies like INSM and INVA. INSM's stock price could see a boost if the upcoming trial data meets or exceeds expectations, while INVA's stable royalty streams continue to attract investors, as seen in Dauntless' increased stake.

What to watch next: Investors should closely monitor INSM's upcoming phase 3 data from its Arikayce trial, expected in the second half of 2021. Additionally, INVA's Q2 2021 earnings, scheduled for August 2021, will provide insights into the company's recurring royalty performance. Lastly, any changes in Dauntless Investment Group's position in INVA could signal further investor sentiment shifts.